Geron survives, for now, but the jury at J&J is still out on the future of imetelstat
Geron has survived another scrape with disaster, but it’s still operating under a dark cloud.
This morning the biotech announced that J&J’s review of the data from two studies of its drug imetelstat warranted continued work in myelodysplastic syndromes and myelofibrosis. But the pharma giant $JNJ is still reserving the right to quit if the data don’t hold up later in the year.
That’s not a big vote of confidence.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.